Skip to content
AlternativeMed

Wavelength, Irradiance and Dose as Research Variables

Why wavelength, irradiance, fluence and timing are separate research variables, why trial results cannot be transferred between devices, and how to read dose reporting.

Content last updated . This page has not been medically reviewed.

Why dose is a research problem

When a trial says light "worked", the result belongs to the exact light that was delivered, not to light in general. Researchers describe that light with several variables. Reviews of photobiomodulation (PBM) say that inconsistent dosimetry, methods and reporting across studies limit clinical translation. [1] This page explains the variables so you can read a study or product page critically. It deliberately gives no recommended values, because published trial settings are not instructions.

The main variables, in plain words

VariableWhat it describesWhy it matters when comparing
WavelengthThe color of the light (red or near-infrared are most studied), measured in nanometersDifferent wavelengths penetrate and interact with tissue differently [1]
IrradianceHow intense the light is at the skin surface (power per area)A device's rated power is not the same as light reaching the skin
Fluence (energy density)Total energy delivered per area, which depends on intensity and timeTwo sessions with different intensity and time can deliver the same or different fluence
Pulse structureContinuous or pulsed deliveryNot all studies report it, and effects may differ
Timing and number of sessionsWhen and how often light is deliveredResults at short and long follow-up may differ
Beam and areaLaser versus LED, spot size, distanceA laser is coherent and collimated; LEDs are not laser diodes [2][3]
Tissue opticsSkin color, thickness, depth of targetTissue optical properties differ between animal models and humans [1]

The "biphasic" idea, and why it complicates things

Reviews describe a biphasic dose-response, where a middle amount may work better than too little or too much. [1] This is a laboratory-derived idea. It does not mean a home device can be tuned to a "sweet spot" without trial data for that device, population and outcome. The same review points to uncertainty in how much light actually reaches deeper tissue. [1]

Reporting problems

  • A review of low-power laser dosimetry noted that experimental and clinical results are hard to compare because a long list of physical and biological parameters should be checked and parts are omitted or inaccurately reported. It counted more than three dozen suggested parameters across authors. [4]
  • The Cochrane review of light therapies for acne found that interventions differed greatly in wavelength, dose and comparators, which made most comparisons impossible. [5]
  • The diabetic-foot-ulcer Cochrane review lists comparison of different output power, wavelength, power density and dose ranges as a question, but found trials small and at unclear or high risk of bias. [6]

What dose analyses in trials can and cannot tell you

Some reviews group trials by dose ranges recommended by a laser-therapy association. In knee osteoarthritis, the subgroup within recommended ranges showed a larger pain reduction than all trials combined. [7] This kind of subgroup finding generates hypotheses, and the authors include association officials, a disclosed potential conflict of interest. [7] A different review of tendinopathy found that recommended-dose trials reduced pain but with wide intervals. [8] Neither review tells a reader what setting to use on any device.

Questions to ask about any light claim

  1. Which wavelength, and was it measured or only printed on the label?
  2. Was irradiance measured at the skin, or is it a rated power?
  3. Was the tested device the same as the one being sold?
  4. What was compared against (sham light, no treatment, exercise)?
  5. Was the outcome a symptom, a function or a lab marker?
  6. Who funded the study?

More tools are in How to Evaluate a Health Device: A Verified-Specification Checklist and Light Device Specifications: Wavelength, Irradiance and Dose. The device-by-device view is on Device-Specific Evidence for Light Therapy Products.

Frequently asked questions

What is the difference between irradiance and dose?

Irradiance is how intense the light is at a moment; dose usually refers to the energy delivered over a session. Studies define them differently, so check the definition.

Can I use published trial settings at home?

Not safely or reliably. Trial settings belong to the device, population and clinical oversight used in that study. [4]

Why do two red-light studies disagree?

Different wavelength, power, timing, devices, populations and outcomes can all differ, and reporting is often incomplete. [1][4]

More details: evidence, limits and cautions

The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.

Safety
More light is not automatically better, and bright or laser-class sources can injure eyes and skin; see Eye and Skin Risks of Light Devices. The FDA's general-wellness guidance gives a laser product claiming skin rejuvenation as an example of a technology that presents risks of skin and eye burns. [9]
References
  1. Ahmed R, et al. Photobiomodulation for skeletal muscle regeneration: mechanisms, dosimetry, and translational challenges. Front Bioeng Biotechnol. 2026. Read 2026-10-22.
  2. U.S. Food and Drug Administration. Laser Products and Instruments. Read 2026-10-22.
  3. U.S. Food and Drug Administration. Product Classification: powered light based laser non-thermal instrument for adjunctive use in pain therapy (NHN). Read 2026-10-22.
  4. da Fonseca AS. Is there a measure for low power laser dose? Lasers Med Sci. 2019. Read 2026-10-22.
  5. Barbaric J, et al. Light therapies for acne. Cochrane Database Syst Rev. 2016. Read 2026-10-22.
  6. Wang HT, et al. Phototherapy for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2017. Read 2026-10-22.
  7. Stausholm MB, et al. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis. BMJ Open. 2019. Read 2026-10-22.
  8. Naterstad IF, et al. Efficacy of low-level laser therapy in patients with lower extremity tendinopathy or plantar fasciitis. BMJ Open. 2022. Read 2026-10-22.
  9. U.S. Food and Drug Administration. General Wellness: Policy for Low Risk Devices (guidance issued January 6, 2026). Read 2026-10-22.
Education, not medical advice. This page is for general information. It does not diagnose or treat any condition and is not a substitute for care from a qualified health professional. Natural does not automatically mean safe. Ask a clinician or pharmacist before changing your care, especially if you take medication, are pregnant or breastfeeding, or have a health condition.